BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/5/2014 11:43:00 AM | Browse: 1068 | Download: 1259
Publication Name World Journal of Gastroenterology
Manuscript ID 7338
Country Japan
Received
2013-11-14 07:52
Peer-Review Started
2013-11-14 17:24
To Make the First Decision
2013-12-16 17:16
Return for Revision
2013-12-17 13:57
Revised
2014-01-06 14:46
Second Decision
2014-06-17 09:11
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-06-17 09:41
Articles in Press
2014-06-17 10:07
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-11-04 10:53
Publish the Manuscript Online
2014-11-20 20:51
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Autobiography
Article Title MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice
Manuscript Source Invited Manuscript
All Author List Tatsuya Ohyama, Ken Sato, Yuichi Yamazaki, Hiroaki Hashizume, Norio Horiguchi, Satoru Kakizaki, Masatomo Mori, Motoyasu Kusano and Masanobu Yamada
Funding Agency and Grant Number
Funding Agency Grant Number
Merck Sharp and Dohme
Corresponding Author Ken Sato, M.D., Ph.D., Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan. Phone: +81-27-220-8127 Fax: +81-27-220-8136 E-mail: satoken@showa.gunma-u.ac.jp
Key Words Dipeptidyl peptidase-4 inhibitor; Hepatic steatosis; ob/ob mice; AMP-activated protein kinase; Microsomal triglyceride transfer protein; Adiponectin
Core Tip Administration of a DPP-4 inhibitor, MK-0626 ameliorated hepatic steatosis, serum ALT levels, glucose levels, insulin levels and calculated HOMA scores and increased serum adiponectin levels in ob/ob mice. MK-0626 treatment significantly increased the mRNA expression of peroxisome proliferator-activated receptor α and microsomal triglyceride transfer protein but significantly reduced sterol regulatory element binding transcription factor-1c, fatty acid synthase and stearoyl-CoA desaturase-1. The activity of AMP-activated protein kinase (AMPK) was significantly increased. These results suggested that MK-0626 could attenuate hepatic steatosis through enhancing AMPK activity, inhibiting hepatic lipogenic gene expression, enhancing triglyceride secretion from liver and increasing serum adiponectin levels.
Publish Date 2014-11-20 20:51
Citation Ohyama T, Sato K, Yamazaki Y, Hashizume H, Horiguchi N, Kakizaki S, Mori M, Kusano M, Yamada M. MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice. World J Gastroenterol 2014; 20(43): 16227-16235
URL http://www.wjgnet.com/1007-9327/full/v20/i43/16227.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i43.16227
Full Article (PDF) WJG-20-16227.pdf
Full Article (Word) WJG-20-16227.doc
Manuscript File 7338-Review.doc
Answering Reviewers 7338-Answering reviewers.pdf
Copyright License Agreement 7338-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 7338-Language certificate.pdf
Peer-review Report 7338-Peer reviews.pdf
Scientific Misconduct Check 7338-CrossCheck.jpg
Scientific Editor Work List 7338-Scientific editor work list.pdf